NYSE:NGM - NGM Biopharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.38
  • Forecasted Upside: 31.55 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$23.85
▲ +1.07 (4.70%)
1 month | 3 months | 12 months
Get New NGM Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NGM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NGM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$31.38
▲ +31.55% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for NGM Biopharmaceuticals in the last 3 months. The average price target is $31.38, with a high forecast of $39.00 and a low forecast of $28.00. The average price target represents a 31.55% upside from the last price of $23.85.
Buy
The current consensus among 8 contributing investment analysts is to buy stock in NGM Biopharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2020Chardan CapitalReiterated RatingBuy$39.00High
i
Rating by M. Morabito at Chardan Capital
8/14/2020B. RileyReiterated RatingBuy$30.00High
i
Rating by Mayank Mamtani at B. Riley
8/13/2020Chardan CapitalLower Price TargetBuy$40.00 ➝ $39.00High
i
Rating by M. Morabito at Chardan Capital
7/30/2020Piper SandlerInitiated CoverageOverweight$30.00High
i
7/7/2020Chardan CapitalInitiated CoverageBuy$40.00High
i
Rating by M. Morabito at Chardan Capital
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$30.00High
i
5/21/2020B. RileyReiterated RatingBuy$30.00Low
i
Rating by Mayank Mamtani at B. Riley
5/18/2020Stifel NicolausReiterated RatingBuy$32.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
5/14/2020Raymond JamesBoost Price TargetStrong-Buy$31.00 ➝ $32.00Medium
i
Rating by Steven Seedhouse at Raymond James
4/19/2020Raymond JamesInitiated CoverageStrong-Buy$31.00Low
i
Rating by Steven Seedhouse at Raymond James
4/6/2020Raymond JamesInitiated CoverageStrong-Buy$31.00High
i
3/27/2020CitigroupLower Price TargetBuy$34.00 ➝ $28.00High
i
Rating by Joel Beatty at Citigroup Inc.
3/23/2020CowenReiterated RatingBuy$30.00Low
i
3/19/2020Stifel NicolausLower Price TargetBuy$33.00 ➝ $32.00High
i
Rating by Derek Archila at Stifel Nicolaus
3/19/2020B. RileyReiterated RatingBuy$30.00High
i
Rating by Mayank Mamtani at B. Riley
2/26/2020B. RileyBoost Price Target$24.00 ➝ $30.00Low
i
Rating by Mayank Mamtani at B. Riley
2/25/2020Stifel NicolausBoost Price TargetBuy$26.00 ➝ $33.00High
i
Rating by Derek Archila at Stifel Nicolaus
2/25/2020CitigroupBoost Price TargetPositive ➝ Buy$31.00 ➝ $34.00High
i
Rating by Joel Beatty at Citigroup Inc.
2/24/2020B. RileyReiterated RatingBuy$24.00 ➝ $24.00High
i
Rating by Mayank Mamtani at B. Riley
2/24/2020CowenReiterated RatingBuyHigh
i
2/11/2020B. RileyReiterated RatingBuy$24.00Medium
i
Rating by Mayank Mamtani at B. Riley
12/10/2019CitigroupReiterated RatingBuy$31.00Medium
i
12/4/2019Stifel NicolausReiterated RatingBuy$26.00High
i
Rating by Derek Archila at Stifel Nicolaus
10/17/2019B. RileyInitiated CoverageBuy$24.00High
i
Rating by M. Mamtani at B. Riley
8/14/2019Stifel NicolausReiterated RatingBuy$26.00Low
i
6/24/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$26.00High
i
5/20/2019CowenReiterated RatingBuy$25.00Medium
i
4/29/2019CitigroupInitiated CoverageBuy ➝ Buy$29.00High
i
4/29/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$22.00Medium
i
4/29/2019CowenInitiated CoverageOutperform ➝ Outperform$25.00Medium
i
(Data available from 11/29/2015 forward)
NGM Biopharmaceuticals logo
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $23.85
$22.80
$24.09

50 Day Range

MA: $18.92
$16.28
$23.52

52 Week Range

Now: $23.85
$9.24
$24.54

Volume

77,926 shs

Average Volume

263,634 shs

Market Capitalization

$1.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A